CLINICAL TRIALS PROFILE FOR PERMETHRIN

505(b)(2) Clinical Trials for Permethrin

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00244439 ↗	Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice	Completed	Taro Pharmaceuticals USA	Phase 3	2005-12-01	Current treatments for head lice include over-the-counter products such as permethrin and prescription products such as OVIDE (malathion 0.5%) lotion. In a previous phase II study, a novel, easy-to-use malathion 0.5% formulation was found to be a safe treatment for head lice. The current study will compare the efficacy and safety of this novel formulation of malathion with OVIDE and with an over-the-counter permethrin product.
New Formulation	NCT00927472 ↗	Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice	Completed	Taro Pharmaceuticals USA	Phase 3	2009-08-01	In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.
New Formulation	NCT00963508 ↗	Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice	Completed	Taro Pharmaceuticals USA	Phase 3	2009-08-01	In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.

All Clinical Trials for Permethrin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00244439 ↗	Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice	Completed	Taro Pharmaceuticals USA	Phase 3	2005-12-01	Current treatments for head lice include over-the-counter products such as permethrin and prescription products such as OVIDE (malathion 0.5%) lotion. In a previous phase II study, a novel, easy-to-use malathion 0.5% formulation was found to be a safe treatment for head lice. The current study will compare the efficacy and safety of this novel formulation of malathion with OVIDE and with an over-the-counter permethrin product.
NCT00262418 ↗	Comparison of the Efficacy and Safety of Ivermectin to Permethrin	Completed	University Ghent	Phase 2	2004-07-01	Comparison of the efficacy and safety of a single administration of ivermectin to a single administration of permethrin for the treatment of scabies
NCT00376155 ↗	Comparison of Two Strategies for the Delivery of IPTc	Completed	Medical Research Council	Phase 4	2006-05-01	Antimalarial chemoprophylaxis can reduce morbidity and mortality from malaria in children. However, this approach to malaria control has not been implemented widely because of concerns over its possible effect on the development of resistance and natural immunity. Intermittent preventive treatment (IPT) may be able to achieve some of the beneficial effects of chemoprophylaxis without its drawbacks. Recently, it has been shown that IPT given to Senegalese children under the age of five years on three occasions during the malaria transmission season reduced the incidence of clinical malaria by approximately 90%. However, it is uncertain how this intervention can be most effectively delivered. Therefore, 26 Maternal and Child Health (MCH) trekking clinics in Upper River Division, south of the River Gambia, each with an average catchment population of 400-500 children under 5 years of age, will be randomly allocated to receive IPT from the MCH trekking team or from a IPT dispenser (village health worker, traditional birth attendant or a community mother based in a primary health care village). Treatment with a single dose of sulfadoxine /pyrimethamine (SP) plus three doses of amodiaquine will be given to all study subjects at monthly intervals on three occasions during the months of September, October and November. The primary end points will be the incidence of clinical attacks of malaria detected by passive case detection, and cost-effectiveness of the delivery methods. Important secondary endpoints will be the coverage and the equity of coverage of IPT in preventing malaria morbidity.

Clinical Trial Conditions for Permethrin

Condition Name

Condition Name for Permethrin
Intervention	Trials
Scabies	22
Pediculosis Capitis	4
Pediculosis	3

Condition MeSH

Condition MeSH for Permethrin
Intervention	Trials
Scabies	23
Lice Infestations	10
Parasitic Diseases	5

Clinical Trial Locations for Permethrin

Trials by Country

Trials by Country for Permethrin
Location	Trials
United States	45
France	13
Pakistan	5
Dominican Republic	2
Puerto Rico	2

Trials by US State

Trials by US State for Permethrin
Location	Trials
Florida	12
California	8
Texas	6
Pennsylvania	5
Arkansas	3

Clinical Trial Progress for Permethrin

Clinical Trial Phase

Clinical Trial Phase for Permethrin
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	2
PHASE2	1

Clinical Trial Status

Clinical Trial Status for Permethrin
Clinical Trial Phase	Trials
Completed	21
Recruiting	5
NOT_YET_RECRUITING	3

Clinical Trial Sponsors for Permethrin

Sponsor Name

Sponsor Name for Permethrin
Sponsor	Trials
bioRASI, LLC	4
Taro Pharmaceuticals USA	3
Concentrics Research	3

Sponsor Type

Sponsor Type for Permethrin
Sponsor	Trials
Other	44
Industry	30
U.S. Fed	2

Last updated: April 27, 2026

Clinical Trials Update, Market Analysis and Projection for Permethrin

Permethrin is a topical antiparasitic insecticide used primarily for scabies (1% cream/lice (1% lotion) and other ectoparasites. Commercially, it is a mature, off-patent product category with multiple generic manufacturers in the US and EU. The market is driven by recurrent outbreaks, guideline-based first-line positioning for scabies, and OTC or low-barrier prescribing patterns in several regions. The clinical-trials pipeline is thin relative to newer dermatology antiparasitics, with most activity focused on formulation refinement, combination products, and performance in specific populations rather than new molecular entities.

What is permethrin’s current clinical-development posture?

Permethrin’s clinical footprint is dominated by established, already-approved indications. New development is typically formulation-based (vehicle, permeation, stability), dose regimens, or comparative efficacy/safety studies against other antiparasitics (e.g., ivermectin, benzyl benzoate, spinosad, malathion).

Trial types that still appear for permethrin

• Bioequivalence and bridging studies for generic entrants and line extensions
• Comparative efficacy/safety trials for scabies and head lice across age groups
• Formulation studies focused on tolerability (irritation, dermatitis risk) and usability endpoints

Trial types that are uncommon

• First-in-class, mechanism-discovery trials (permethrin is already mechanistically established as a neurotoxin for arthropods)
• Large registrational Phase 3 programs comparable to the newest generation head lice agents, due to a mature evidence base and low exclusivity value

Practical implication for investors

• Pipeline value is mostly tied to product differentiation (vehicle, dosing instructions, patient adherence) and market access execution, not to patent-driven breakthrough biology.

---

What do the latest clinical trials say (and where are they concentrated)?

No single global “latest update” set of permethrin trials can be pinned without a named study list and registry extracts. Under a business standard for investment and R&D decisions, the cleanest read is that permethrin’s clinical activity is not signaling a pivot toward new indications or new molecular IP, but rather supports incremental entry and lifecycle management.

How to interpret the evidence base

• Permethrin retains first-line usage in many scabies protocols, and continues to be a standard comparator in head lice and scabies efficacy trials.
• When new trial outcomes are published, they typically aim to show therapeutic performance is maintained under real-world constraints: adherence to repeat dosing instructions, contact management, and tolerability.

Where trial-like activity tends to show up

• Dermatology and public health contexts where scabies outbreaks drive demand and comparative effectiveness matters
• Pediatric use cases where excipient tolerability and user adherence are often primary endpoints

---

What is the current market size and demand driver profile for permethrin?

Permethrin’s market sits inside broader dermatology and antiparasitic categories. It is usually measured as:

• Scabies topical therapy and
• Head lice topical therapy

Key demand drivers are stable:

• Guideline-based use for scabies
• Recurrent outbreaks in schools and community settings for head lice
• Price-sensitive procurement by payers and public health programs, which favors generics
• Low complexity of distribution (topical availability)

Supply-side profile

• Multiple global generic suppliers compete, reducing pricing power.
• Manufacturing is not constrained by patent barriers, so capacity is less protected and more competitive.

---

How does permethrin market performance compare to newer competitors?

Permethrin faces competitive pressure from newer or easier-to-use agents in head lice and selected scabies settings. The category split is important:

Head lice

• Permethrin 1% lotion has long-standing adoption.
• Newer agents and regimens compete on speed of kill, mosquito-like usability (time-to-application, less re-treatment), and pediculicidal performance.

Scabies

• Permethrin is still a common first-line.
• Ivermectin competes, particularly in systemic-treatment pathways or where adherence for topical regimens is difficult.

What this means for projection

• Permethrin remains resilient due to entrenched guideline presence and generic affordability.
• Upside growth is limited by generic saturation, with share gains more likely in cost-sensitive segments than via premium pricing.

---

What is the near-term market outlook for permethrin (2025 to 2035)?

Base-case outlook (category maturity)

• Stability to modest growth driven by population-level prevalence, outbreak cycles, and incremental share in countries that continue first-line topical use.
• Pricing declines or flat pricing typical of mature generic categories.
• Volume growth depends on public health initiatives, reimbursement structures, and adherence improvements.

Upside scenarios

• Greater adoption in regions with evolving guideline uptake where topical scabies therapy is preferred.
• Product improvements that reduce re-treatment frequency and irritation, supporting better patient adherence.

Downside scenarios

• Continued conversion to alternative actives if clinicians or payers favor newer agents or oral regimens for compliance reasons.
• Shifts toward non-topical pathways in head lice and scabies under payer formularies.

---

What does “market projection” look like in actionable terms?

For a market projection usable by R&D and investment committees, the practical variables are:

1. Unit demand (incidence prevalence and guideline uptake)
2. Price per unit (generic competition and payer reimbursement)
3. Share dynamics (where permethrin remains preferred vs displaced)

Given the mature nature of the molecule and broad generic availability, the projection that matters most is share and pricing, not therapeutic reinvention.

Projection framework (how to model permethrin)

• Start with a topical scabies + head lice addressable population forecast (regional prevalence times treatment rates).
• Apply penetration of permethrin based on guideline and formulary status.
• Apply generic price erosion (annual % decline) constrained by procurement minimums.
• Model substitution by segment:
  • head lice: substitution by newer pediculicides
  • scabies: substitution by oral therapy (where adopted)

---

What can R&D teams still do with permethrin (if the molecule is mature)?

Even in off-patent conditions, development can be commercially meaningful if it reduces friction for prescribers and patients:

• Formulation and vehicle optimization to improve tolerability and adherence
• Combination products where regulatory pathways allow additive value
• Device-led delivery (applicator design, dosing aids) that improves correct use

These programs generally target:

• Faster patient usability
• Reduced irritation
• Improved real-world effectiveness via adherence

---

Key takeaways

• Permethrin is a mature, off-patent antiparasitic topical with clinical evidence that supports ongoing guideline usage for scabies and entrenched use in head lice.
• Clinical development activity is mainly incremental: generic equivalence, bridging, and formulation performance, not new molecular breakthroughs.
• Market growth is constrained by generic competition, so the most material drivers for performance are price erosion, payer/procurement dynamics, and substitution by newer head lice or scabies alternatives.
• Investment and R&D value is concentrated in product differentiation that improves adherence and tolerability and in execution against formularies and public health procurement cycles.

---

FAQs

1) Is permethrin still a first-line option for scabies?
Yes. Permethrin remains widely positioned as a topical first-line scabies therapy in multiple guideline ecosystems, with continuing clinical use supported by a long safety and efficacy record.

2) What drives demand for permethrin products most?
Incidence prevalence cycles (including outbreak-driven surges), guideline adherence, and payer or public health procurement patterns that favor low-cost topical therapies.

3) Why is there less “registrational-style” permethrin development today?
Because permethrin is mature with extensive published efficacy and because generic and lifecycle product pathways reduce the attractiveness of large exclusivity-seeking programs.

4) How does permethrin face competition in head lice?
Newer pediculicides and alternative regimens compete on usability and performance endpoints, which can shift formulary preference even when permethrin remains effective.

5) What differentiations have the best commercial odds for permethrin?
Vehicle and formulation changes that reduce irritation, improve spread/coverage, and simplify application instructions. Delivery and adherence-support design also matters because correct re-treatment timing impacts outcomes.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Permethrin (product labeling and approvals). FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] World Health Organization. (n.d.). Guidelines on scabies and other neglected tropical diseases (treatment recommendations where applicable). WHO. https://www.who.int/
[3] American Academy of Dermatology. (n.d.). Head lice and scabies clinical guidance (therapeutic recommendations). AAD. https://www.aad.org/
[4] National Institute for Health and Care Excellence. (n.d.). Scabies management (topical therapy guidance where applicable). NICE. https://www.nice.org.uk/